Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03995784 | Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B | PHASE2 | COMPLETED | 6 | — | — | Jun 1, 2019 | Apr 1, 2020 | Aug 8, 2021 | - | — |
| Name | Type | Description |
|---|---|---|
| Coagulation Factor IX variant | BIOLOGICAL | Single intravenous injection of CB2679d/Dalcinonacog alfa |